Keywords
- Cystic Fibrosis
- Cystic Fibrosis Transmembrane Conductance Regulator
- Splice Factor
- Splice Pattern
- Splice Mutation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Amaral MD, Pacheco P, Beck S, Farinha CM, Penque D, Nogueira P, Barreto C, Lopes B, Casals T, Dapena J, Gartner S, Vasquez C, Perez-Frias J, Olveira C, Cabanas R, Estivill X, Tzetis M, Kanavakis E, Doudounakis S, Dork T, Tummler B, Girodon-Boulandet E, Cazeneuve C, Goossens M, Blayau M, Verlingue C, Vieira I, Ferec C, Claustres M, des Georges M, Clavel C, Birembaut P, Hubert D, Bienvenu T, Adoun M, Chomel JC, De Boeck K, Cuppens H, Lavinha J (2001) Cystic fibrosis patients with the 3272-26A>G splicing muta-tion have milder disease than F508del homozygotes: a large European study. J Med Genet 38: 777-783
Ars E, Serra E, Garcia J, Kruyer H, Gaona A, Lazaro C, Estivill X (2000) Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet 9: 237-247
Augarten A, Kerem BS, Yahav Y, Noiman S, Rivlin Y, Tal A, Blau H, Ben-Tur L, Szeinberg A, Kerem E (1993) Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849+10 kb C-→T mutation. Lancet 342: 25-26
Aznarez I, Chan EM, Zielenski J, Blencowe BJ, Tsui LC (2003) Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryp-tic splice sites in exon 13 of the cystic fibrosis transmembrane conductance reg-ulator gene. Hum Mol Genet 12: 2031-2040
Beck S, Penque D, Garcia S, Gomes A, Farinha C, Mata L, Gulbenkian S, Gil-Ferreira K, Duarte A, Pacheco P, Barreto C, Lopes B, Cavaco J, Lavinha J, Amaral MD (1999) Cystic fibrosis patients with the 3272-26A→G mutation have mild disease, leaky alternative mRNA splicing, and CFTR protein at the cell membrane. Hum Mutat 14: 133-144
Bienvenu T, Beldjord C, Chelly J, Fonknechten N, Hubert D, Dusser D, Kaplan JC (1996) Analysis of alternative splicing patterns in the cystic fibrosis transmem-brane conductance regulator gene using mRNA derived from lymphoblastoid cells of cystic fibrosis patients. Eur J Hum Genet 4: 127-134
Black DL (2003) Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72: 291-336
Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, Maass G, Tummler B (1992) Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmem-brane-conductance regulator mRNA transcripts in human epithelia. Eur J Biochem 206: 137-149
Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu IY, Wirth B (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12: 2481-2489
Buchner DA, Trudeau M, Meisler MH (2003) SCNM1, a putative RNA splicing factor that modifies disease severity in mice. Science 301: 967-969
Buratti E, Dork T, Zuccato E, Pagani F, Romano M, Baralle FE (2001) Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skip-ping. Embo J 20: 1774-1784.
Caceres JF, Kornblihtt AR (2002) Alternative splicing: multiple control mecha-nisms and involvement in human disease. Trends Genet 18: 186-193
Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3: 285-298
Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 98: 9808-9813.
Chiba-Falek O, Kerem E, Shoshani T, Aviram M, Augarten A, Bentur L, Tal A, Tullis E, Rahat A, Kerem B (1998) The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C-→T mutation. Genomics 53: 276-283
Chiba-Falek O, Parad RB, Kerem E, Kerem B (1999) Variable levels of normal RNA in different organs carrying the CFTR splicing mutation 3849+10 kb C→T. Am J Respir Crit Care Med 159: 1998-2002
Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, Romey MC, Ruiz-Romero J, Verlingue C, Claustres M (1995a) Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 332: 1475-1480
Chillon M, Dork T, Casals T, Gimenez J, Fonknechten N, Will K, Ramos D, Nunes V, Estivill X (1995b) A novel donor splice site in intron 11 of the CFTR gene, created by mutation 1811+1.6kbA→G, produces a new exon: high frequency in Spanish cystic fibrosis chromosomes and association with severe phenotype. Am J Hum Genet 56: 623-629
Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG (1993) Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 3: 151-156
Claustres M, Guittard C, Bozon D, Chevalier F, Verlingue C, Ferec C, Girodon E, Cazeneuve C, Bienvenu T, Lalau G, Dumur V, Feldmann D, Bieth E, Blayau M, Clavel C, Creveaux I, Malinge MC, Monnier N, Malzac P, Mittre H, Chomel JC, Bonnefont JP, Iron A, Chery M, Georges MD (2000) Spectrum of CFTR muta-tions in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat 16: 143-156
Collins FS (1992) Cystic fibrosis: molecular biology and therapeutic implications. Science 256: 774-779
Coolidge CJ, Seely RJ, Patton JG (1997) Functional analysis of the polypyrimidine tract in pre-mRNA splicing. Nucleic Acids Res 25: 888-896
Dreyfus DH, Bethel R, Gelfand EW (1996) Cystic fibrosis 3849+10 kb C >T muta-tion associated with severe pulmonary disease and male fertility. Am J Respir Crit Care Med 153: 858-860
Dugueperoux I, De Braekeleer M (2005) The CFTR 3849+10kbC→T and 2789+5G→A alleles are associated with a mild CF phenotype. Eur Respir J 25: 468-473
Estivill X, Bancells C, Ramos C (1997) Geographic distribution and regional ori-gin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum Mutat 10: 135-154
Faustino NA, Cooper TA (2003) Pre-mRNA splicing and human disease. Genes Dev 17: 419-437
Friedman K, Kole J, Cohn JA, Knowles MR, Silverman LM, Kole R (1999) Correction of aberrant splicing of the cystic fibrosis transmembrane conduc-tance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem 274: 36193-36199
Frizzel RA (1995) Functions of the cystic fibrosis transmembrane conductance regulator protein. Am J Respir Crit Care Med 151: S54-S58
Gabriel SE, Clarke LL, Boucher RC, Stutts MJ (1993) CFTR and outward rectify-ing chloride channels are distinct proteins with a regulatory relationship. Nature 363: 263-268
Gilbert F, Li Z, Arzimanoglou II, Bialer M, Denning C, Gorvoy J, Honorof J, Ores C, Quittell L (1995) Clinical spectrum in homozygotes and compound heterozygotes inheriting cystic fibrosis mutation 3849+10kbC >T: significance for geneticists. Am J Med Genet 58: 356-359
Greger R, Schreiber R, Mall M, Wissner A, Hopf A, Briel M, Bleich M, Warth R, Kunzelmann K (2001) Cystic fibrosis and CFTR. Pflugers Arch 443 Suppl 1: S3-7
Hamosh A, Corey M (1996) Variable phenotypes for nine CFTR mutations associated with pancreatic sufficiency in cystic fibrosis (CF) patients. Am J Hum Genet S59: 25
Hefferon TW, Broackes-Carter FC, Harris A, Cutting GR (2002) Atypical 5′ splice sites cause CFTR exon 9 to be vulnerable to skipping. Am J Hum Genet 71: 294-303
Hefferon TW, Groman JD, Yurk CE, Cutting GR (2004) A variable dinucleotide repeat in the CFTR gene contributes to phenotype diversity by forming RNA secondary structures that alter splicing. Proc Natl Acad Sci USA 101: 3504-3509
Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spock A, Gorvoy JD, Quittel L, Friedman KJ, Silverman LM (1994) A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride con-centrations. N Engl J Med 331: 974-980
Highsmith WE, Burch LH, Zhou Z, Olsen JC, Strong TV, Smith T, Friedman KJ, Silverman LM, Boucher RC, Collins FS, Knowles MR (1997) Identification of a splice site mutation (2789 + 5 G >A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis. Hum Mutat 9: 332-338
Hull J, Shackleton S, Harris A (1994) Analysis of mutations and alternative splicing patterns in the CFTR gene using mRNA derived from nasal epithelial cells. Hum Mol Genet 3: 1141-1146
Imperiale MJ, Akusjnarvi G, Leppard KN (1995) Post-transcriptional control of adenovirus gene expression. Curr Top Microbiol Immunol 199: 139-171
Jarvi K, Zielenski J, Wilschanski M, Durie P, Buckspan M, Tullis E, Markiewicz D, Tsui LC (1995) Cystic fibrosis transmembrane conductance regulator and obstructive azoospermia. Lancet 345: 1578
Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245: 1073-1080
Kerem E, Kalman YM, Yahav Y, Shoshani T, Abeliovich D, Szeinberg A, Rivlin J, Blau H, Tal A, Bentur L (1995) Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel. Hum Genet 96: 193-197
Kerem E, Rave-Harel N, Augarten A, Madgar I, Nissim-Rafinia M, Yahav Y, Goshen R, Bentur L, Rivlin J, Aviram M, Genem A, Chiba-Falek O, Kraemer MR, Simon A, Branski D, Kerem B (1997) A cystic fibrosis transmembrane conduc-tance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am J Respir Crit Care Med 155: 1914-1920
Kunzelmann K, Schreiber R, Nitschke R, Mall M (2000) Control of epithelial Na+ conductance by the cystic fibrosis transmembrane conductance regulator. Pflugers Arch 440: 193-201
Larriba S, Bassas L, Gimenez J, Ramos MD, Segura A, Nunes V, Estivill X, Casals T (1998) Testicular CFTR splice variants in patients with congenital absence of the vas deferens. Hum Mol Genet 7: 1739-1743
Li C, Ramjeesingh M, Wang W, Garami E, Hewryk M, Lee D, Rommens JM, Galley K, Bear CE (1996) ATPase activity of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 271: 28463-28468
Liu HX, Cartegni L, Zhang MQ, Krainer AR (2001) A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27: 55-58.
Mak V, Jarvi KA, Zielenski J, Durie P, Tsui LC (1997) Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens. Hum Mol Genet 6: 2099-2107
McIntosh I, Cutting GR (1992) Cystic fibrosis transmembrane conductance regu-lator and the etiology and pathogenesis of cystic fibrosis. FASEB J 6: 2775-2782
Nissim-Rafinia M, Chiba-Falek O, Sharon G, Boss A, Kerem B (2000) Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum Mol Genet 9: 1771-1778
Nissim-Rafinia M, Kerem B (2002) Splicing regulation as a potential genetic modifier. Trends Genet 18: 123-127
Nissim-Rafinia M, Aviram M, Randell SH, Shushi L, Ozeri E, Chiba-Falek O, Eidelman O, Pollard HB, Yankaskas JR, Kerem B (2004) Restoration of the cys-tic fibrosis transmembrane conductance regulator function by splicing modula-tion. EMBO Rep 5: 1071-1077
Noone PG, Pue CA, Zhou Z, Friedman KJ, Wakeling EL, Ganeshananthan M, Simon RH, Silverman LM, Knowles MR (2000) Lung disease associated with the IVS8 5T allele of the CFTR gene [In Process Citation]. Am J Respir Crit Care Med 162: 1919-1924
Nordqvist K, Ohman K, Akusjarvi G (1994) Human adenovirus encodes two pro-teins which have opposite effects on accumulation of alternatively spliced mRNAs. Mol Cell Biol 14: 437-445
Orgad S, Neumann S, Loewenthal R, Netanelov-Shapira I, Gazit E (2001) Prevalence of cystic fibrosis mutations in Israeli Jews. Genet Test 5: 47-52
Pagani F, Buratti E, Stuani C, Romano M, Zuccato E, Niksic M, Giglio L, Faraguna D, Baralle FE (2000) Splicing factors induce cystic fibrosis transmem-brane regulator exon 9 skipping through a nonevolutionary conserved intronic element. J Biol Chem 275: 21041-21047.
Pagani F, Buratti E, Stuani C, Baralle FE (2003a) Missense, nonsense, and neutral mutations define juxtaposed regulatory elements of splicing in cystic fibrosis transmembrane regulator exon 9. J Biol Chem 278: 26580-26588
Pagani F, Stuani C, Tzetis M, Kanavakis E, Efthymiadou A, Doudounakis S, Casals T, Baralle FE (2003b) New type of disease causing mutations: the exam-ple of the composite exonic regulatory elements of splicing in CFTR exon 12. Hum Mol Genet 12: 1111-1120
Ramalho AS, Beck S, Meyer M, Penque D, Cutting GR, Amaral MD (2002) Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol 27: 619-627
Ramalho AS, Beck S, Penque D, Gonska T, Seydewitz HH, Mall M, Amaral MD (2003) Transcript analysis of the cystic fibrosis splicing mutation 1525-1G>A shows use of multiple alternative splicing sites and suggests a putative role of exonic splicing enhancers. J Med Genet 40: e88
Rave-Harel N, Kerem E, Nissim-Rafinia M, Madjar I, Goshen R, Augarten A, Rahat A, Hurwitz A, Darvasi A, Kerem B (1997) The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am J Hum Genet 60: 87-94
Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073
Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245: 1059-1065
Slomski R, Schloesser M, Berg LP, Wagner M, Kakkar VV, Cooper DN, Reiss J (1992) Omission of exon 12 in cystic fibrosis transmembrane conductance regulator (CFTR) gene transcripts. Hum Genet 89: 615-619
Strong TV, Wilkinson DJ, Mansoura MK, Devor DC, Henze K, Yang Y, Wilson JM, Cohn JA, Dawson DC, Frizzell RA (1993) Expression of an abundant alterna-tively spliced form of the cystic fibrosis transmembrane conductance regulator (CFTR) gene is not associated with a cAMP-activated chloride conductance. Hum Mol Genet 2: 225-230
Teraoka SN, Telatar M, Becker-Catania S, Liang T, Onengut S, Tolun A, Chessa L, Sanal O, Bernatowska E, Gatti RA, Concannon P (1999) Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. Am J Hum Genet 64: 1617-1631
Welsh MJ, Anderson MP, Rich DP, Berger HA, Denning GM, Ostedgaard LS, Sheppard DN, Cheng SH, Gregory RJ, Smith AE (1992) Cystic fibrosis trans-membrane conductance regulator: a chloride channel with novel regulation. Neuron 8: 821-829
Welsh MJ, Tsui LC, Boat T.F, Beaudet AL (1995) In Scriver CL, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, pp 3799-3876
Zielenski J, Bozon D, Markiewicz D, Aubin G, Simard F, Rommens JM, Tsui LC (1993) Analysis of CFTR transcripts in nasal epithelial cells and lymphoblasts of a cystic fibrosis patient with 621+1G→T and 711+1G→T mutations. Hum Mol Genet 2: 683-687
Zielenski J, Tsui LC (1995) Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 29: 777-807
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Nissim-Rafinia, M., Kerem, B. (2006). Splicing Modulation as a Modifier of the CFTR Function. In: Jeanteur, P. (eds) Alternative Splicing and Disease. Progress in Molecular and Subcellular Biology, vol 44. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34449-0_10
Download citation
DOI: https://doi.org/10.1007/978-3-540-34449-0_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-34448-3
Online ISBN: 978-3-540-34449-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)